Can a cancer drug beat CLL fatigue? new study hopes so
NCT ID NCT02131584
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This study tests whether the drug Jakafi (ruxolitinib) can reduce severe fatigue in people with chronic lymphocytic leukemia (CLL). Ten participants who have CLL but do not yet need standard treatment will take Jakafi and report their fatigue levels. The goal is to see if blocking a certain protein can improve energy and shrink swollen lymph nodes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.